Cas no 101143-86-6 ((R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol)

(R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol structure
101143-86-6 structure
Product Name:(R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol
CAS No:101143-86-6
MF:C20H24N2O2
MW:324.416765213013
CID:2077715
PubChem ID:6916033
Update Time:2025-10-23

(R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol Chemical and Physical Properties

Names and Identifiers

    • (+)-(8R,9S)-6'-methoxyinchonan-9-ol
    • (+)-quinidine
    • (8R,9S)-QD-H
    • (9S)-6'-methoxycinchonan-9-ol
    • 2B,H2SO4-Quinidine
    • NSC10004
    • QD
    • QDH
    • QID
    • quinidine
    • quinine
    • Ro-01-0633
    • (R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol
    • (3alpha,8alpha,9R)-6'-methoxycinchonan-9-ol
    • 101143-86-6
    • DTXSID001293139
    • (R)-[(2S,4S,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
    • SCHEMBL6353578
    • (3I+/-,8I+/-,9R)-6a(2)-Methoxycinchonan-9-ol
    • Cinchonan-9-ol, 6'-methoxy-, (3alpha,8alpha,9R)-
    • EN300-258512
    • Inchi： 1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14+,19+,20-/m1/s1
    • InChI Key： LOUPRKONTZGTKE-BBNYVJOESA-N
    • SMILES： O[C@H](C1C=CN=C2C=CC(=CC=12)OC)[C@@H]1C[C@@H]2CCN1C[C@H]2C=C

Computed Properties

  • Exact Mass: 324.183778g/mol
  • Monoisotopic Mass: 324.183778g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 4
  • Heavy Atom Count: 24
  • Rotatable Bond Count: 4
  • Complexity: 457
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 4
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Molecular Weight: 324.4g/mol
  • XLogP3: 2.9
  • Topological Polar Surface Area: 45.6?2

Experimental Properties

  • Color/Form: CRYSTALS WITH 2.5 MOL WATER OF CRYSTALLIZATION; CRYSTALS FROM DILUTE ALCOHOL
  • Melting Point: 331 to 336 °F (NTP, 1992)
  • Solubility: less than 0.1 mg/mL at 64° F (NTP, 1992)
  • LogP: 3.44

(R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Enamine
EN300-258512-0.05g
(R)-[(2S,4S,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
 101143-86-6 95%
0.05g
 $2755.0 2024-06-18

(R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol Related Literature

Related Categories

Additional information on (R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol

Research Briefing on (R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl(6-methoxyquinolin-4-yl)methanol (CAS: 101143-86-6)

In recent years, the compound (R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl(6-methoxyquinolin-4-yl)methanol (CAS: 101143-86-6) has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique bicyclic structure and quinoline moiety, has shown promising potential in various therapeutic applications, particularly in the modulation of neurological and inflammatory pathways. The following briefing provides an overview of the latest research developments related to this compound, including its synthesis, mechanism of action, and preclinical evaluations.

The synthesis of (R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl(6-methoxyquinolin-4-yl)methanol has been optimized in recent studies to improve yield and enantiomeric purity. Researchers have employed asymmetric catalytic methods and advanced purification techniques to achieve high stereoselectivity, which is critical for its biological activity. The compound's structural complexity poses challenges in large-scale production, but recent advancements in flow chemistry and biocatalysis have shown promise in addressing these issues.

Mechanistic studies have revealed that this compound acts as a potent modulator of nicotinic acetylcholine receptors (nAChRs), particularly the α7 subtype. Its ability to selectively bind and activate these receptors has implications for treating cognitive disorders such as Alzheimer's disease and schizophrenia. Additionally, its anti-inflammatory properties, mediated through the cholinergic anti-inflammatory pathway, are being explored for conditions like rheumatoid arthritis and inflammatory bowel disease. Recent in vitro and in vivo studies have demonstrated its efficacy in reducing pro-inflammatory cytokines and improving cognitive function in animal models.

Preclinical evaluations have further highlighted the compound's favorable pharmacokinetic profile, including good oral bioavailability and blood-brain barrier penetration. However, challenges such as metabolic stability and potential off-target effects require further investigation. Collaborative efforts between academic institutions and pharmaceutical companies are underway to develop derivatives with improved safety and efficacy profiles. These efforts are supported by computational modeling and high-throughput screening to identify optimal structural modifications.

In conclusion, (R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl(6-methoxyquinolin-4-yl)methanol represents a promising candidate for therapeutic development in neurology and inflammation. Ongoing research aims to address the remaining challenges and advance this compound toward clinical trials. The integration of synthetic chemistry, pharmacology, and translational research will be pivotal in realizing its full potential.

101143-86-6 ((R)-(2S,4S,5S)-5-ethenyl-1-azabicyclo2.2.2octan-2-yl(6-methoxyquinolin-4-yl)methanol) Related Products

Recommended suppliers
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Amadis Chemical Company Limited
NewCan Biotech Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
NewCan Biotech Limited
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Essenoi Fine Chemical Co., Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent